Clinical Trials Logo

Viraemia clinical trials

View clinical trials related to Viraemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01883206 Completed - Viraemia Clinical Trials

CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response

Start date: September 2013
Phase: N/A
Study type: Observational

The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and to have the previous samples retested using different methods which have been further developed in different laboratories. Also, to prepare monoclonal antibodies from the B lymphocytes of these patients and define their strength. If potent antibodies are identified, the investigators would like to consider developing them further to see if they can protect future transplant patients against cytomegalovirus.

NCT ID: NCT00947141 Completed - Viraemia Clinical Trials

Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)

Start date: February 2003
Phase: Phase 4
Study type: Interventional

This study aims to determine: a) whether those patients with 'low level' viral load results (between 200 and 3,000 copies/ml) could be monitored as opposed to starting preemptive therapy with valganciclovir, ganciclovir and/or foscarnet; b) whether those patients with 'high level' viral load results (above 3,000 copies/ml) could stop preemptive therapy earlier, thus maximising the benefits of therapy and minimising its risks.